Friday Market

Posted Aug 24, 2011

DUBLIN–(BUSINESS WIRE)– Research and Markets (http://www.researchandmarkets.com/research/0851d3/the_immunomodulato) has announced a further of a “The Immunomodulators Market Outlook to 2016” news to their offering.

The news provides endless coverage of a tellurian immunomodulators market, incorporating illness overviews, and epidemiological analyses. This news captures and assesses heading marketed products, RD pipelines, sales foresee and pivotal marketplace players. It also highlights pivotal trends that will change sales by 2016.

Features and benefits

• Assess a studious intensity and diagnosis trends of a vital defence associated diseases globally.
• Analyse a dynamics of a immunomodulators marketplace and know a impact of pivotal RD events, marketplace trends, and issues.
• Gain present rival comprehension and know a vital issues inspiring pivotal curative marketers.
• Identify a heading tube products in a foresee sales to 2016.
• Develop strategies for success in a destiny CNS market.

Highlights

TNF inhibitors indicated for a diagnosis of rheumatoid arthritis, psoriasis and inflammatory bowel illness shaped a largest share of a market, with a tip 3 products: Remicade, Humira and Enbrel accounting for 40.1% of a marketplace in 2010.

Novartis’ orally formulated Gilenya for mixed sclerosis will benefit endless marketplace share reaching sales of $2.3bn by 2016. Copaxone and Avonex sales will decrease strongly to 2016.

GSK and Human Genome Sciences’ Benlysta was a initial product to be authorized for a diagnosis of systemic lupus erythematous in a past 30 years, a pivotal step in a illness treatment. Benlysta will strech sales of $401m in 2016.

Your pivotal questions answered

• What are a stream expansion drivers in a tellurian immunomodulator market?
• What are a new healing approaches in a immunomodulators marketplace and that of these offer poignant intensity in a future?
• What is a foresee blurb intensity of a many earnest compounds in clinical development?
• Who are a heading players in any denote in a immunomodulators market, and what are their strategies?
• How will a launch of late theatre tube products and obvious expires impact a marketplace to 2016?

For some-more information revisit http://www.researchandmarkets.com/research/0851d3/the_immunomodulato

Source: Business Insights

CONTACT:

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo